Shanghai Pharmaceuticals Holding Co (上海醫藥集團), China’s second-largest drugmaker, is raising US$550 million from investors, including Temasek Holdings Pte and Pfizer Inc, to fund acquisitions in the world’s fastest growing major economy.
The sale of shares to the investors, which also include Hong Kong-based Guoco Group (國浩集團) and Bank of China Group Investment Ltd (中銀集團投資), is part of Shanghai Pharma’s plans to raise as much as US$2.2 billion in an offering of stock in Hong Kong, according to a term sheet sent to investors yesterday.
The funds will enable Shanghai Pharma to purchase drug-manufacturing assets in China, where demand for medicines is forecast by IMS Health Inc to expand at least 25 percent this year. A soon-to-be-released government plan may push for the nation’s three biggest drug companies to increase their share of the market to 30 to 35 percent by 2015 from 21 percent in 2009, the 21st Century Business Herald reported last week.
“Shanghai Pharma should benefit from upcoming industry consolidation, since it is already one of the biggest players,” said Pan Lei, an analyst at Guodu Securities Co (國都證券), who recommends buying the shares. “The company is seen as an attractive investment because its drug distribution business makes it stable.”
Singapore state investment firm Temasek will invest US$300 million, Guoco Group will invest US$150 million and Pfizer and Bank of China Group Investment will each buy US$50 million of shares, according to the document. The new shares in the Hong Kong offering will be sold at HK$21.80 to HK$26 apiece.
Shanghai Pharma will use 30 percent of proceeds from its Hong Kong offering to buy other drug companies and allocate 40 percent to expand and strengthen its distribution networks, according to the term sheet.
Shanghai Pharmaceuticals has suspended trading in Shanghai until after its Hong Kong shares begin trading, scheduled for May 20, according to the term sheet.
Temasek and Pfizer said they weren’t currently able to comment on the investment. Guoco and Bank of China Investment Group didn’t immediately respond to requests for comment.
NEW IDENTITY: Known for its software, India has expanded into hardware, with its semiconductor industry growing from US$38bn in 2023 to US$45bn to US$50bn India on Saturday inaugurated its first semiconductor assembly and test facility, a milestone in the government’s push to reduce dependence on foreign chipmakers and stake a claim in a sector dominated by China. Indian Prime Minister Narendra Modi opened US firm Micron Technology Inc’s semiconductor assembly, test and packaging unit in his home state of Gujarat, hailing the “dawn of a new era” for India’s technology ambitions. “When young Indians look back in the future, they will see this decade as the turning point in our tech future,” Modi told the event, which was broadcast on his YouTube channel. The plant would convert
Nanya Technology Corp (南亞科技) yesterday said the DRAM supply crunch could extend through 2028, as the artificial intelligence (AI) boom has led the world’s major memory makers to dramatically reduce production of standard DRAM and allocate a significant portion of their capacity for high-bandwidth memory (HBM) chips. The most severe supply constraints would stretch to the first half of next year due to “very limited” increases in new DRAM capacity worldwide, Nanya Technology president Lee Pei-ing (李培瑛) told a news briefing. The company plans to increase monthly 12-inch wafer capacity to 20,000 in the first half of 2028 after a
Property transactions in the nation’s six special municipalities plunged last month, as a lengthy Lunar New Year holiday combined with ongoing credit tightening dampened housing market activity, data compiled by local land administration offices released on Monday showed. The six cities recorded a total of 10,480 property transfers last month, down 42.5 percent from January and marking the second-lowest monthly level on record, the data showed. “The sharp drop largely reflected seasonal factors and tighter credit conditions,” Evertrust Rehouse Co (永慶房屋) deputy research manager Chen Chin-ping (陳金萍) said. The nine-day Lunar New Year holiday fell in February this year, reducing
New vehicle sales in Taiwan plunged about 37 percent sequentially last month as the long Lunar New Year holiday and 228 Peace Memorial Day holiday cut short the number of working days, along with the lingering uncertainty over import tax cuts on US vehicles, market researcher U-Car said in a report yesterday. New car sales last month totaled 22,043, slumping from 35,073 units in January and down 19.89 percent from 37,515 in February last year, U-Car data showed. Sales of imported luxury cars, led by Mercedes-Benz, plummeted about 45 percent to 3,109 units last month from 5,663 units in the previous month,
RSS